Please login to the form below

Not currently logged in

Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head

Moves to the Boston company from Onyx Pharmaceuticals
Intarcia Therapeutics Sunita Zalani

Boston-based biopharmaceutical firm Intarcia Therapeutics has appointed Dr Sunita Zalani as vice president, global head of regulatory affairs and quality.

She joins the company from Amgen's Onyx Pharmaceuticals subsiary, where she served as vice president of global regulatory affairs.

Dr Zalani had been with Onyx - which was acquired by Amgen last year - since 2004 and prior to that worked at Lilly as its global regulatory lead.

In her new role at Inarcia, whose most advanced prospect is a phase III version of the diabetes drug exenatide that only needs to be given once a year, Dr Zalani will sit on the leadership team and report directly to chairman, president and CEO Kurt Graves.

He said: "We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had.

“Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry.”

6th August 2014

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...